

What: Special Update: Vaccine Committee Agenda
 Date & Time: July 31, 2025; 11:00 a.m. - 12:00 p.m. PT
 Location: Webinar/Teleconference – Individual Links Will be Sent to Each Attendee

Notice: The meeting may be recorded for the benefit of the minute-taker. The WVA intends to delete the recording after the minutes are approved.

Agenda

Approx. Time	Pg.		Topic/[Anticipated Action]	Presented by:
11:00 - 11:05 a.m.			1. Welcome & Introductions a. Notification of Recording	E. Marcuse/J. Zell
11:05 – 11:10 a.m.	Pg. 3-4	*	2. Action Items a. Approve April 17, 2025 Meeting Minutes	E. Marcuse
11:10 - 11:20 a.m.			3. Recent Events & WA Response a. Measles/Pertussis b. ACIP, FDA, HHS reorganization & WA Response, VAC c. Issues on Horizon: Thimerosal/Hep B	E. Marcuse/J. Dunn
11:20 -11:35 a.m.			4. Clinical Physicians Perspective a. Family's response b. Effect on practice	Committee Members
11:35 - 11:40 a.m.			5. Public Comment	
11:40 -11:50 p.m.			6. Fall Ordering a. Flu/Flumist b. COVID-19 c. RSV d. Impact of Budget Cuts	J. Jorgenson
11:50 – 12:00 p.m.			7. Limiting Vaccine Loss	J. Zell
12:00 p.m.			8. Closing	E. Marcuse

*Indicates additional materials / Red text indicates an action item

July 31, 2025

WVA Meeting of the Vaccine Committee

Proposed Form of Votes

The following are suggested forms of votes only. They are intended to be an aid to facilitate work by individual directors and committee members.

Items under Agenda Section X:

VOTED: To approve April 17, 2025 meeting minutes.

[To approve April 17, 2025 meeting with the changes suggested at the meeting.]

Meeting Minutes
Vaccine Committee Meeting
April 17, 2025; 11:30 a.m. – 12:30 p.m. PT

- I. Attendance.** This meeting was conducted virtually. Participating in all or part of the meeting were the following individuals:

Members

Ed Marcuse, MD, Emeritus Professor of
Pediatrics, University of Washington, *Chair*
Hema Sivasubramanian, MD, Aetna
John Dunn, MD, MPH, Kaiser
Jeff Gombosky, Pharmaceutical Research and
Manufacturers of America
Carrie Jenner, MD, Pierce County Immunization
Coalition (PCIC)
Sherri Zorn, MD, DOH & WVA Consultant
Amy Carter, MD, Allegro Pediatrics
Kristi A. Rice, MD, Providence
Gretchen Lasalle, MD, Rockwood Clinic
Libby Page, MPH, King County Public Health
Amy Person, MD, Benton-Franklin Health District
Jennifer Maxwell, MD, Yakima Medical Dental
Clinic
Jamilia Sherls-Jones, DNP, MPH, Washington
Department of Health

Michele Roberts, MPH, MCHES, Washington
Department of Health

WVA

Julia G. Zell, MA, Esq., Executive Director
Cheri Cagle, Stakeholder Liaison
Kerrie Walker, Deputy Manager

Helms & Company, Inc.

Patrick Miller, MPH, WVA, Administrative
Director
Ashley Ithal, MPH, Project Support Leader

Other

Breelyn Young, GSK
Ajia McAferty, WithinReach WA
Juliet Dang, Seqirus
Bob Runnells, Informed Choice WA

II. Summary of Actions Taken and/or Recommended

Actions Taken (votes adopted)

- i. To approve Vaccine Committee meeting minutes November 7, 2024.

III. Minutes

Welcome and Introductions

At 11:30 a.m. Dr. Marcuse called the meeting to order and announced that the meeting would be recorded for the benefit of the minute taker, to be deleted once the minutes are approved.

Calendar Consent Items

Dr. Marcuse asked for a motion to approve the minutes. Upon motion duly made and seconded, it was unanimously

- i. **VOTED: To approve Vaccine Committee meeting minutes November 7, 2024.**

IV. Public Comments

Dr. Marcuse invited members of the public to speak if they had comments. Public comments were received from Mr. Runnells from Informed Choice Washington.

V. DOH Immunization Program Updates

RSV (Nirsevimab) Update

Ms. Sherls noted that the 2024–2025 Nirsevimab (RSV monoclonal antibody) season concluded at the end of March in alignment with CDC guidance. She reported that 33,284 doses were administered this season compared to 15,654 last season; noting that administration began earlier (September vs. October) which may have contributed to higher

volume. Dr. Carter shared an article entitled “Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus” <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831181>

Influenza Update

Ms. Sherls reported that the 2024–2025 flu season saw elevated levels of flu activity nationally and within Washington State. She reported high hospitalization rates and pediatric deaths, including a small number in Washington. Ms. Sherls noted that child influenza vaccination rates have declined sharply, from 44.5% (2019–2020) to 26.8% (2024–2025) in individuals under 18, likely due to vaccine confidence erosion. Influenza vaccine must be pre-bought in February for influenza season, unlike RSV and COVID vaccines which are ordered monthly, so accurate projections are critical.

COVID-19 Vaccine Update

Ms. Sherls reported that demand for the COVID-19 vaccine has significantly declined, leading to product wastage due to shorter expiration dates and strict storage requirements. She noted that many providers are required to stock minimum CDC-required doses (e.g., 10 doses), even when their actual usage is lower.

Ms. Sherls shared the “Pop-up Vaccination Clinic Guide” document <https://doh.wa.gov/sites/default/files/2024-02/348-1021-PopUpVaccinationClinicGuide.pdf>

VI. WVA Updates

Ms. Zell highlighted ongoing issues with provider billing and assessment collection. She noted that the WVA is working with the DOH on solutions to identify sources of Vaccine Assessment Loss (VAL). Mr. Miller added that in the current fiscal year, WVA has funded more vaccines than collected DBAs which has decreased reserve fund levels.

VII. Revised Vaccine Committee Charter Discussion

Dr. Marcuse reviewed proposed revisions with the WVA Vaccine Committee Charter with the Committee. He requested feedback on potential changes, discussion ensued, and several edits were suggested for consideration at the upcoming WVA Board meeting.

VIII. Challenging Times

Dr. Marcuse expressed serious concern of the impact of federal cuts to CDC funding and public health infrastructure. He emphasized the essential role of academic public health researchers (e.g., PhDs, Fellows) and the long-term implications of dismantling the foundation. The Committee discussed how these changes could weaken vaccine acceptance, research, and system innovation. Dr. Dunn remarked that while the Committee has previously not had to make difficult prioritization decisions, the current and future climate may require it.

IX. Closing

The meeting adjourned at 12:31 p.m. PT.